AstraZeneca is likely to boost Q1 spending to ready camizestrant for breast cancer and baxdrostat for hypertension, UBS notes. The firm appears to have redirected Farxiga resources toward baxdrostat pre‑launch, while inventory cuts ahead of Farxiga’s generic entry could dent sales. Oncology staples Imfinzi, Tagrisso and Calquence are expected to keep revenue strong. Shares edged up 0.75% to £153.90.

Novartis investors will watch late‑stage pipeline cues after the Swiss group warned of a weak first‑half, UBS analysts say. Focus will center on remibrutinib for multiple sclerosis, pelacarsen for cardiovascular risk and del‑desiran for myotonic dystrophy type 1. Ongoing generic pressure on Entresto, Tasigna and Promacta should accelerate sales erosion, yet Kisqali and Scemblix are forecast to deliver solid results. Shares rose 0.6%.

Roche’s next diagnostic update will dominate investor attention, with CEO Thomas Schinecker slated to outline top‑line growth and margin outlook on May 12, UBS notes. Recent trial data for giredestrant in breast cancer, fenebrutinib in multiple sclerosis and Gazyva in systemic lupus sharpen expectations for the group’s broader portfolio. No formal mid‑term guidance is anticipated, but the market rewarded the stock with a 0.8% rise.